Form D · Pharmaceuticals
Abide Therapeutics, Inc.
Princeton, NJ · CIK 0001535138
Offering snapshot reported Nov 18, 2011 · SEC filing
- Reported sold
- $2.2M Offering amount: $2.25M
- Investors reported
- 3 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 7, 2011 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 18, 2011 | Initial | $2,199,999 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-168913
Source: Form D, filed Nov 18, 2011. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| John Clarke | Director |
| Benjamine Cravatt | Director |
| Alan Ezekowitz | Director, Executive |
| Paul Schimmel | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
230 Nassau Street
Princeton, NJ, 08542
Princeton, NJ, 08542